DocDollars

Optinose Us, Inc.

PA · United States · Reporting entity ID 100000011125

Total reported 2019–2025
$15.5M
#383 of 2,960 reporting companies — 0% of all reported industry payments
$9.37M in general payments across 110,777 records, plus $6.08M in research funding across 990 records.

How it breaks down

General payments $9,373,283
Research funding $6,080,587

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Optinose Us, Inc. reported $15.5M to US doctors and teaching hospitals from 2019 to 2025, ranking #383 of 2,960 reporting companies. 39% of that was research funding and 61% general payments such as consulting, speaking, food and travel. 110,777 general payment records and 990 research records were filed.

Common questions about Optinose Us, Inc.

How much has Optinose Us, Inc. paid US doctors?

Optinose Us, Inc. reported $15,453,871 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $9,373,283 in general payments, $6,080,587 in research funding.

How does Optinose Us, Inc. rank among drug and device companies?

It ranks #383 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Optinose Us, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.